The University of Kansas has synthesized TNF-α (ARE sequence)/ELAV-like protein 1 (HuR) interaction inhibitors. They are reported to be useful for the treatment of cancer, kidney fibrosis, liver fibrosis, pulmonary fibrosis and myocardial fibrosis.